Clinical Trial Update: Efalizumab in the Treatment of Alopecia, Phase II [Phase 2]

View source ↗

Summary

Phase II trial of efalizumab for Alopecia Totalis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Totalis

Drugs mentioned

• Raptiva (efalizumab) (efalizumab)

Snippet

Sponsor: Northwestern University | Conditions: Alopecia Totalis | Phase 2 | Status: WITHDRAWN